ClinicalTrials.gg
CompletedNCT03872232Updated Jan 15, 2021

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan

A Phase 3 interventional study of Ezetimibe/Rosuvastatin and Telmisartan in Hypercholesterolemia and Hypertension, sponsored by Addpharma Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-01-15.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
40th of 97
180 · median 148
Started
2019
with 1 other
Phase 3
50 of 98
1 open now
Registered
84th of 98
by date
Lead sponsor
2 of 98
Addpharma Inc.

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 40th largest by enrollment of the 97 interventional ones that give a count, is one of 2 that started in 2019, is one of 50 in phase 3, and was the 84th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension.

Read the detailed description

This trial is a phase 3 study to evaluate efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension.

In "Rosuvastatin/Ezetimibe+Telmisartan" treatment group, 60 subjects will be assigned and the subjects administer "Rosuvastatin/Ezetimibe+Telmisartan" for 8 weeks.

In "Rosuvastatin/Ezetimibe" treatment group, 60 subjects will be assigned and the subjects administer "Rosuvastatin/Ezetimibe" for 8 weeks.

In "Telmisartan" treatment group, 60 subjects will be assigned and the subjects administer "Telmisartan" for 8 weeks.

03

Conditions studied

  • Hypercholesterolemia
  • Hypertension
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Subjects with hypertension and hyperlipidemia

Exclusion criteria

Exclusion Criteria:

  • Patient with known or suspected secondary hypertension
  • Other exclusions applied
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Ezetimibe/Rosuvastatin and Telmisartan

    60 subjects will be assigned and the subjects will be administered "Ezetimibe/Rosuvastatin and Telmisartan" for 8 weeks.

    Drug: Ezetimibe/Rosuvastatin · Drug: Telmisartan

  • Active comparator
    Ezetimibe/Rosuvastatin

    60 subjects will be assigned and the subjects will be administered "Ezetimibe/Rosuvastatin" for 8 weeks.

    Drug: Ezetimibe/Rosuvastatin

  • Active comparator
    Telmisartan

    60 subjects will be assigned and the subjects will be administered "Telmisartan" for 8 weeks.

    Drug: Telmisartan

Interventions

  • DrugEzetimibe/Rosuvastatin

    Drug pages: Ezetimibe · Rosuvastatin

    PO, Once daily(QD), 8weeks

    Also known as: Rosuvamibe Tab.

  • PO, Once daily(QD), 8weeks

    Also known as: Micardis Tab.

06

What researchers measure

Primary outcomes

  1. Low density lipoprotein cholesterol (LDL-C)

    LDL-C change at Week 8 compared to Baseline

    Time frame: Baseline, Week 8

  2. Mean sitting systolic blood pressure (MSSBP)

    MSSBP change at Week 8 compared to Baseline

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Mean sitting systolic blood pressure (MSSBP)

    MSSBP change at Week 4 compared to Baseline

    Time frame: Baseline, Week 4

  2. Low density lipoprotein cholesterol (LDL-C)

    LDL-C change at Week 4 compared to Baseline

    Time frame: Baseline, Week 4

  3. Mean sitting diastolic blood pressure (MSDBP)

    MSDBP change at Week 4, 8 compared to Baseline

    Time frame: Baseline, Week 4, Week 8

  4. Total Cholesterol (TC)

    TC change at Week 4, 8 compared to Baseline

    Time frame: Baseline, Week 4, Week 8

  5. High density lipoprotein cholesterol (HDL-C)

    HDL-C change at Week 4, 8 compared to Baseline

    Time frame: Baseline, Week 4, Week 8

  6. Triglyceride (TG)

    TG change at Week 4, 8 compared to Baseline

    Time frame: Baseline, Week 4, Week 8

  7. Low density lipoprotein cholesterol/High density lipoprotein cholesterol (LDL-C/HDL-C)

    LDL-C/HDL-C change at Week 4, 8 compared to Baseline

    Time frame: Baseline, Week 4, Week 8

  8. Total Cholesterol/High density lipoprotein cholesterol (TC/HDL-C)

    TC/HDL-C change at Week 4,8 compared to Baseline

    Time frame: Baseline, Week 4, Week 8

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Aug 2020, 17 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 17 months is close to that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2019
First posted
Mar 13, 2019
StartActual
Feb 26, 2019
Primary completionActual
Aug 12, 2020
CompletionActual
Aug 12, 2020
Last update
Jan 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03872232
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Mar 13, 2019
Start date
Feb 26, 2019
Primary completion
Aug 12, 2020
Completion
Aug 12, 2020
Last update
Jan 15, 2021

Study contacts

Hyo Soo Kim, M.D., Ph.D
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Rosuvastatin · Telmisartan

Start the discussion